



Next generation Glucose-1-phosphate thymidyltransferase (RmlA) inhibitors: An extended SAR study to direct future design

Ganyuan Xiao^{a,1}, Magnus S. Alphey^{a,1}, Fanny Tran^a, Lisa Pirrie^a, Pierre Milbeo^a, Yi Zhou^a, Jasmine K. Bickel^a, Oxana Kempf^a, Karl Kempf^a, James H. Naismith^{b,*}, Nicholas J. Westwood^{a,*}

^a School of Chemistry and Biomedical Sciences Research Complex, University of St Andrews and EaStCHEM, St Andrews Fife KY16 9ST, UK

^b Division of Structural Biology, University of Oxford, and The Rosalind Franklin Institute, Harwell Campus, OX11 0FA, UK

ARTICLE INFO

Keywords:

Antibacterial drug discovery
Bacterial cell wall synthesis
RmlA
Structure-based optimization

ABSTRACT

The monosaccharide L-Rhamnose is an important component of bacterial cell walls. The first step in the L-rhamnose biosynthetic pathway is catalysed by glucose-1-phosphate thymidyltransferase (RmlA), which condenses glucose-1-phosphate (Glu-1-P) with deoxythymidine triphosphate (dTTP) to yield dTDP-D-glucose. In addition to the active site where catalysis of this reaction occurs, RmlA has an allosteric site that is important for its function. Building on previous reports, SAR studies have explored further the allosteric site, leading to the identification of very potent *P. aeruginosa* RmlA inhibitors. Modification at the C6-NH₂ of the inhibitor's pyrimidinedione core structure was tolerated. X-ray crystallographic analysis of the complexes of *P. aeruginosa* RmlA with the novel analogues revealed that C6-aminoalkyl substituents can be used to position a modifiable amine just outside the allosteric pocket. This opens up the possibility of linking a siderophore to this class of inhibitor with the goal of enhancing bacterial cell wall permeability.

1. Introduction

The continued global emergence of multi-drug resistant bacteria is a major health concern. The time taken for resistance to new drugs to arise is often rapid and the pace of antibiotic discovery has slowed since the golden era of the 1940–60s.¹ The development of novel antimicrobials that avoid the existing mechanisms of resistance and target new pathways is recognised as a high priority for research.

The outer membrane (OM) protects gram-negative bacteria from antibiotic attack and is essential for survival.² The OM is composed of lipopolysaccharides (LPS) that in many, but not all, bacteria contain L-rhamnose, a C6 sugar unit. For example, in *P. aeruginosa* L-rhamnose is a component of the LPS and deletion of one of the genes responsible for its biosynthesis results in a bacterium that has much lower virulence in a mouse model.³ In *M. tuberculosis* the arabinogalactan unit in the cell wall is linked to the peptidoglycan by a disaccharide phosphodiester linker that has a L-rhamnose component (a decaprenyl-diphospho-N-acetylglucosamine rhamnosyl molecule⁴). The enzymes involved in the biosynthesis of L-rhamnose are therefore potential anti-tuberculosis drug

targets.^{5–6} The L-rhamnose biosynthetic pathway involves four enzymes, RmlA-RmlD, which catalyse the conversion of glucose-1-phosphate (Glu-1-P) to the L-rhamnose precursor deoxythymidine diphosphate-L-rhamnose (dTDP-L-rhamnose³, Scheme 1). Since this biosynthetic pathway is not found in eukaryotes, these enzymes are attractive targets for the development of novel selective antibiotics. Small molecule inhibitors of RmlA^{7–9} and RmlC^{10–11} have already been reported.


RmlA, a glucose-1-phosphate thymidyltransferase, is the first enzyme in the pathway and catalyses the condensation of Glu-1-P with deoxythymidine triphosphate (dTTP) to give dTDP-D-glucose (Scheme 1).^{3,12} The inhibition of RmlA by dTDP-L-rhamnose (the final product of the four step reaction sequence) has been reported^{3,13} and it would therefore appear that, in bacteria, RmlA is the point of control for flux through the biosynthetic pathway. RmlA exists as a dimer of dimers and is functional as a tetramer. As a consequence of its structure, the active sites cluster at the dimer-dimer interface and the allosteric (or regulatory) sites cluster at the monomer–monomer interface within each dimer.^{3,14}

We have previously reported a series of potent novel small molecule

* Corresponding authors.

E-mail addresses: james.naismith@strubi.ox.ac.uk (J.H. Naismith), njw3@st-andrews.ac.uk (N.J. Westwood).

¹ These authors contributed equally.



Scheme 1. L-Rhamnose biosynthetic pathway involving 4 enzymes which catalyse the conversion of Glu-1-P to dTDP-L-rhamnose.

allosteric inhibitors of *P. aeruginosa* RmlA⁷ (for example **Compound 8a** in **Figure 1A**, compound numbering taken from the original report⁷). In the previous work⁷, examples of our *in vitro* RmlA inhibitors were tested for their ability to inhibit the growth of *M. tuberculosis* (H37Rv) in which RmlA has been shown to be essential.¹⁵ Even though sequence alignment of RmlA from *P. aeruginosa* and *M. tuberculosis* showed the two proteins are highly conserved, the selected compounds demonstrated only weak activity against *M. tuberculosis* bacteria (MIC₁₀₀ values > 25 µg/mL). For example, the potent *in vitro* *P. aeruginosa* RmlA inhibitor **8a** (IC₅₀ = 0.073 ± 0.001 µM⁷) was shown to have only a weak effect on *M. tuberculosis* (MIC₁₀₀ = 100 µg/mL). Apart from off-target effects and minor sequence differences in the RmlA homologues from the two bacteria, another possible reason for the poor effect on live bacteria is the inability of the tested analogues to penetrate the bacterial cells. The cell envelope of mycobacteria, comprised of polysaccharides and lipids, functions as a natural shield that is effective at blocking the entry of small molecules into the protoplasm.^{16–17}

Re-examination of the RmlA-**8a** complex [PDB 4ASJ] revealed a hydrophobic pocket that was only partly occupied by the N¹-substituent (**Figures 1B and 1C**). In an initial attempt to explore further the impact of structural changes on the binding of compound **8a**, we chose to vary the R₁ substituent (**Figure 1A**). However, the main focus of this report builds on the observation that the C6-NH₂ group of **8a** points out of the allosteric binding pocket based on our analysis of the RmlA-**8a** complex (**Figure 1C**). It was decided to assess whether substitution of one of the NH bonds in the C6-NH₂ group with an extended alkyl chain (represented by R₂ in **Figure 1A**) could be tolerated by *P. aeruginosa* RmlA as this could provide a vector out of the allosteric pocket to an open space whilst retaining the *in vitro* inhibitory activity of the current series of





Figure 1. A. Chemical structure and biological activity of the previously optimized inhibitor **8a**. [7] IC₅₀ against the *Pseudomonas aeruginosa* RmlA protein, MIC₁₀₀ against *Mycobacterium tuberculosis*. The aims of this work were to modify the N¹- and C6-NH₂ positions. B. A representation of **8a** bound in the allosteric site of RmlA based on our previous X-ray crystallographic analysis of the RmlA-**8a** complex [PDB 4ASJ]. Residues that make up the N¹-substituent sub-pocket are highlighted. C. Schematic representation of pocket interactions between **8a** and the enzyme showing that the C6-NH₂ in **8a** has the tendency to point out of the allosteric pocket into solution.



analogues. If successful this could provide the foundation for the development of a new series of RmlA inhibitors. For example, the attachment of a bacterial cell wall permeabilizer could be achieved via the newly incorporated linker unit at the C6-NH₂ position.


2. Results and discussion

Our previous studies focused on structure activity relationship (SAR) analyses involving the sulfonamide and N^{5a}-alkyl substituents in **8a** (Figure 1A).¹⁸ However, no attempts to optimize the substituent at the N¹-position were made. This current study started with examination of the reported structure of the RmlA-**8a** complex [PDB 4ASJ] and revealed that the N¹-substituent pocket was formed from both main- and side-chain atoms of residues Leu45, His119, Glu120, Ile256, Arg259 and Gln260 (Figure 1B). Visual inspection showed that this binding pocket was not ideally filled by the unsubstituted N¹-benzyl group in **8a** and therefore it was proposed that alternative N¹-substituents could improve target binding. A pilot SAR study was performed to explore this hypothesis (see linked Data in Brief report for a detailed discussion). In summary, it was concluded that the key driver in increasing the potency was the presence of a substituent at the 4-position of the N¹-benzyl group. It was found that a *para*-bromobenzyl substituent (compound **1a** in Table 1) was optimal (see linked Data in Brief report and PDB codes 5FUH, 5FYE, 5FUO, 5FTS, 5FTV, 5FU8). Consequently, all R₂-modified analogues were prepared in the N¹-*p*-bromobenzyl series with one exception (compound **1f**, Scheme 2 and Table 1).

The X-ray crystallographic analysis of the RmlA-**1a** complex (Figure 2, PDB 5FTV) confirmed that in the *p*-bromobenzyl series, as well as for **8a**, substitution at the C6-NH₂ position should enable positioning of a modifiable functional group in proximity to the mouth of the allosteric site (Figure S1A). If this could be achieved, not only would the only remaining position available for modification in this inhibitor series have been explored, but future efforts to prepare analogues with enhanced bacterial cell wall permeability would also be facilitated (Figures S1B and S1C). Preliminary molecular modelling studies predicted that the C6-NH₂ modified analogue **1b** (Table 1 and Scheme 2 for structure) binds in the allosteric site of the enzyme in a similar confirmation to the parent analogue **1a** (Figure S2). In addition, the extended C6-aminoalkyl chain was predicted to reach out towards the mouth of the allosteric pocket, as designed. Analogues **1b** and **1c** with *n*-propyl and ethyl-containing linkers were therefore synthesised (Scheme 2).

It was decided to incorporate the extended C6-aminoalkyl chains of

Table 1
Inhibition data against *P. aeruginosa* RmlA for analogues **1a** – **1f**.



Entry	Compd. ^[a]	R ₁	R ₂	% Inhibition at 10 μM	IC ₅₀ (μM) ^[b]
1	1a	4-BrC ₆ H ₄	H	100	0.034 ± 0.002
2	1b	4-BrC ₆ H ₄	(CH ₂) ₃ NHCH ₃	100	0.860 ± 0.096
3	1c	4-BrC ₆ H ₄	(CH ₂) ₂ NHCH ₃	0	–
4	1d	4-BrC ₆ H ₄	(CH ₂) ₄ NH ₂	100	0.303 ± 0.026
5	1e	4-BrC ₆ H ₄	(CH ₂) ₅ NH ₂	100	0.316 ± 0.023
6	1f	Ph	(CH ₂) ₃ -N ₃ -CH ₂ -NH ₂	100	2.470 ± 0.020

[a] The following PDB codes are assigned to structures of the complexes of RmlA bound to **1b** (6TQG), **1d** (6T38), **1f** (6T37); [b] SD, standard deviation (n = 3).

1b and **1c** early in the reaction sequence (Scheme 2). Selective N¹-alkylation of the starting material 6-chlorouracil (**2**) with 4-bromobenzyl chloride under basic conditions enabled isolation of the N¹-benzylated product to give **3a**.^{19–20} 6-Aminouracils **4b** and **4c** were then synthesized by reaction of **3a** with the corresponding amines **5b** (2 × CH₂) and **5c** (3 × CH₂) in moderate yield. The remaining steps – bromination (to give **6b** and **6c**), addition of methylamine (to give **7b** and **7c**) and sulfonamide formation were based on our previous report⁷ (see linked Data in Brief report for additional examples of this reaction sequence) and enabled the successful conversion of **4b** and **4c** to the *N*-Boc protected versions (**8b** and **8c**) of the final compounds. Subsequent Boc deprotection of **8b** and **8c** using TFA gave **1b** and **1c** respectively as the TFA salts (Scheme 2).

The introduction of the ethyl C6 aminoalkyl chain in **1c** led to a complete loss of activity²¹ against *P. aeruginosa* RmlA, whereas incorporation of the *n*-propyl linker in **1b** retained activity (IC₅₀ of 0.86 μM, Table 1, entries 2 and 3, see Figures S3 and S4 legends for a discussion on the lack of activity of **1c**). X-ray crystallographic analysis of the complex of RmlA with **1b** [PDB 6TQG] showed that **1b** was bound in the allosteric site of RmlA as expected. Compared with the C6-NH₂ unsubstituted analogue **1a** (Table 1, entry 1), most of the ligand–protein interactions were retained in the RmlA-**1b** complex (Figure S5), however, some differences were observed. For example, whereas the C6-NH₂ group in **1a** showed hydrogen bonding to the protein backbone (Gly115 and His119) through the interaction with two different molecules of water, **1b** retained the interaction with Gly115 but lost the water-mediated hydrogen bond to His119 (as expected, Figure S3). Consistent with the docking studies, the extended aminoalkyl chain in **1b** pointed out of the allosteric pocket and the distance between the nitrogen of the newly introduced terminal methylamine in **1b** to the C-terminal Tyr293 residue was 3.8 Å. The terminal NH in **1b** interacted with a network of water molecules ultimately linking to the C-terminal Tyr293 (Figure S3).

Based on the initial success with **1b** being a sub-micromolar inhibitor of *P. aeruginosa* RmlA, it was decided to extend the length of the linker unit from *n*-propyl in **1b** to *n*-butyl in **1d** and *n*-pentyl in **1e** (Scheme 2) in an attempt to position the terminus of the C6-aminoalkyl chain outside the allosteric pocket. In the case of **1d** and **1e**, a primary amine was incorporated at the end of the chain (see Figure S5 legend for more discussions). There was a risk that the more extended and flexible alkyl chains in **1d** and **1e** may undergo hydrophobic collapse. Therefore a heteroaromatic ring was incorporated into the linker unit in an attempt to minimise the chances of this occurring. The triazole-containing compound **1f** was therefore synthesised (Scheme 2). In the case of **1f**, the *para*-Br in the N¹-benzyl moiety was also removed to provide additional room for the triazole group in **1f** to adjust its position in the allosteric site. The synthesis of the additional analogues **1d** and **1e** was achieved in an analogous manner to the synthesis of **1b** and **1c** (Scheme 2). The synthesis of **1f** required incorporation of an azide functional group at the terminus of the C6-linker unit through formation of **4f** (n = 3, R₂ = N₃, Scheme 2). The azide group was compatible with the subsequent steps enabling **4f** to be successfully converted to **8f**. The copper-catalysed azide-alkyne click (CuAAC) reaction of **8f** with propargylamine gave **1f** although the unoptimized yields over the final two steps in the sequence were low (Scheme 2). If analogue **1f** was found to retain activity against *P. aeruginosa* RmlA, future work should enable the relatively easy incorporation of a bacterial cell wall permeabilizer using this CuAAC approach.

The increased length of the linker chain in analogues **1d** and **1e** compared to **1b** led to around a 2.5-fold increase in potency with **1d** and **1e** having IC₅₀ values of 0.303 ± 0.026 μM and 0.316 ± 0.023 μM respectively (Table 1, entries 4 and 5 vs. entry 2). The structure of the RmlA-**1d** complex [PDB 6 T38] confirmed that instead of interacting with any protein residues, the terminal amine of the C6-aminoalkyl chain in **1d** was positioned out of the pocket, approximately equidistant between His119 and Tyr293 (Figures 3A and 3B).





Figure 2. A representation of the X-ray crystallographic analysis of the RmlA-**8a** complex (blue, [PDB 4ASJJ]) overlaid with the analysis of the RmlA-**1a** complex (yellow, [PDB 5FTV]). A subtle change in the positioning of the *N*¹-benzyl group resulted from the bromine atom being present in the 4-position of inhibitor **1a**.

Whilst there was a notable decrease in the potency of the triazole-containing analogue **1f** in the RmlA inhibition assay compared to **1c**, **1d** and **1e** (Table 1, entry 6 vs. entries 2, 4 and 5), **1f** was still able to inhibit *P. aeruginosa* RmlA. The structure of the RmlA-**1f** complex [PDB 6T37] revealed that the triazole moiety of **1f** stacks between the imidazole ring of His119 and its own benzyl group in the *N*¹ position forming an unusual sandwich structure in which the extended C6 chain in **1f** is stabilized (Figure 3C). The terminal NH₂ in **1f** does not appear to interact with any protein residues and extends out of the pocket (Figure 3D and Figure S6). Superposition of the structures of the RmlA-**8a** with RmlA-**1f** complexes (Figure S7) revealed that the introduction of the triazole moiety in **1f** forces the repositioning of its *N*¹-benzyl group. Compared to the situation with **8a**, the *N*¹-benzyl group in **1f** is positioned much closer to Arg 259 and Glu 255 which form the backbone of the hydrophobic pocket. This may be one factor in explaining the observed drop in potency associated with **1f**.

The physicochemical properties (Table S1) of this series of new compounds in terms of Ligand Efficiency (LE, ranging from 0.21 to 0.37)

and Lipophilic Ligand Efficiency (LLE, ranging from 3.9 to 5.2) showed high drug-likeness²², while the cLogP values (ranging from 1.14 – 2.77) are relatively higher than those of therapeutic antibacterial agents, which mostly cluster near 0.²³ To address the possible low permeability of these compounds (due to their relative high lipophilicity), a “trojan horse strategy”²⁴ could be considered. Due to the poor solubility of Fe³⁺ salts, most microorganisms cannot use them directly. A siderophore is an iron chelator secreted by bacteria. Having chelated Fe³⁺, the siderophore is recognised by a specific outer membrane receptor and then transported to the bacterial cytoplasm. In this way the bacteria can take in iron as an essential nutrient required to survive.²⁵ Similarly, synthesised siderophore-antibiotic conjugates^{26–28} can be recognised by bacteria and transported into the cell. As soon as the conjugates are transported into the cell, the antibiotic, if the siderophore-antibiotic linkage is designed correctly, can be released to kill the bacteria. Many studies have shown that synthetic siderophore-drug conjugates can act as novel antimicrobial agents and can help treat disease caused by antibiotic resistant bacteria. The terminal amine of **1d** and **1f** could provide a possible site to attach a siderophore, laying the foundation to prepare bacterial cell wall penetrating RmlA inhibitors. In addition, the presence of the more basic amine functionalities in these novel compounds may impact on activity against both gram positive and gram negative bacteria (the eNTRY rules^{29,30}).

3. Conclusions

A significant extension of our previous studies⁷ on the inhibition of *P. aeruginosa* RmlA, the first enzyme in the L-rhamnose biosynthetic pathway, by pyrimidinedione-based compounds is reported. A pilot SAR study involving modifications at the *N*¹ position of the heterocyclic core led to the identification of a number of potent inhibitors of *P. aeruginosa* RmlA including the *p*-bromo-benzyl substituted analogue **1a**. Subsequent modification at the C6-NH₂ position showed that different linker lengths at this position were tolerated. Throughout these studies detailed analysis of the binding modes of the compounds has been possible by X-ray crystallographic analysis of a large number of RmlA-inhibitor complexes. One highlight from this structural study is the demonstration that for inhibitors **1d** and **1f** the terminus of the newly incorporated linker unit sits outside the allosteric binding pocket. This provides a real opportunity, in future work, to attach a siderophore to the end of the linker unit with the goal of potentially increasing the bacterial cell wall permeability of this class of inhibitors through the ability of the siderophore to be sequestered by the bacterium.³¹




Figure 3. A. Representation of X-ray crystallographic analysis of the RmlA-1d complex [PDB 6T38] showing that the terminal amine of the C6-aminoalkyl chain in 1d has moved out of the pocket and C6-aminoalkyl chain in 1d was situated halfway between His119 and Tyr293. B. The surface representation of the complex of RmlA with 1d revealed that the terminal amine in the aminoalkyl chain at the C6-NH position of 1d had moved out into open space. C. Representation of X-ray crystallographic analysis of the RmlA-1f complex [PDB 6T37] showing that the triazole moiety of 1f stacks between the imidazole ring of His119 in RmlA and the N^1 -benzyl group and the terminal amine in the aminoalkyl chain at the C6-NH position of 1f was positioned in open space outside the allosteric pocket. D. The surface representation of the complex of RmlA with 1f revealed that the terminal NH_2 of 1f is out in the open.

4. Experimental section

4.1. Synthesis of analogues

All intermediates and final compounds were prepared according to the protocols supplied in the [Supporting Information](#) and Data in Brief. Examples of the synthesis of 1d (intermediates and final compound) and the synthesis of 1b, 1c, 1e and 1f (final compounds) are shown below.

4.2. 1-Benzyl-6-chloropyrimidine-2,4(1H,3H)-dione (3a)

A mixture of 6-chlorouracil 2 (5.0 g, 34.2 mmol, 1.0 eq.), 4-bromobenzyl chloride (10.5 g, 51.3 mmol, 1.5 eq.), and K_2CO_3 (2.3 g, 17.1 mmol, 0.5 eq.) in DMSO (100.0 mL, 3.0 mL/mmol) was stirred at 65 °C for 30 min. 10 % aqueous solution of NaOH (100.0 mL, 3.0 mL/mmol) was added to the hot reaction mixture with stirring. The reaction mixture was washed with ethyl acetate (100.0 mL, 3.0 mL/mmol), and the aqueous phase was acidified with conc. aqueous HCl to pH = 2. The resulting aqueous mixture was kept in a refrigerator, and the resulting precipitate was collected by filtration, washed with water (60.0 mL, 2.0 mL/mmol), and dried. 3a was obtained as a white solid (4.4 g, 13.9 mmol, 38 %). Mp. 183–187 °C. 1H NMR (500 MHz, DMSO- d_6) δ 11.77 (1H, s, NH), 7.57 (2H, d, J = 8.4 Hz, H3', H5'), 7.25 (2H, d, J = 8.4 Hz,

H2', H6'), 6.02 (1H, s, H5), 5.12 (2H, s, CH_2). ^{13}C NMR (125 MHz, DMSO- d_6) δ 161.5 (C4), 151.0 (C2), 147.1 (C6), 136.2 (C1'), 132.0 (C3' and C5'), 129.3 (C2' and C6'), 121.0 (C4'), 103.0 (C5), 48.1 (NCH $_2$). HRMS (ES $^+$) m/z calculated for $C_{11}H_9^{79}BrClN_2O_2$. $[M + H]^+$: 314.9536; found: 314.9537.

4.3. Tert-butyl (4-((3-(4-bromobenzyl)-2,6-dioxo-1,2,3,6-tetrahydropyrimidin-4-yl) amino)butyl)carbamate (4d)

To a stirred solution of 1-benzyl-6-chlorouracil 3a (4.0 g, 12.7 mmol, 1.0 eq.) in ethanol (38.0 mL, 3.0 mL/mmol), tert-butyl (4-aminobutyl) carbamate 5d (4.8 g, 25.4 mmol, 2.0 eq.) was added. The resulting yellow solution was stirred at 100 °C in a sealed tube for 3 h. The solvent was evaporated *in vacuo*, and the crude product was purified by column chromatography (50% EtOAc in petroleum ether). 4d was obtained as a yellow solid (3.0 g, 6.3 mmol, 50 %). Mp. 286–288 °C. ν_{max} cm^{-1} 3342 (N–H), 2983 (C–H), 2871 (C–H), 1705 (C=O), 1665 (C=O), 1605 (N–H), 1530 (N–H), 1447 (C=C), 1387 (N–C), 1163 (C–C(=O)-O), 777 (Ar C–H), 669 (C-Br). 1H NMR (500 MHz, $CDCl_3$) δ 10.05 (1H, s, H3), 7.44 (2H, d, J = 7.9 Hz, H3' and H5'), 7.13 (2H, d, J = 8.1 Hz, H2' and H6'), 5.59 (1H, s, H1'), 5.17 (2H, s, NCH $_2$), 4.86 (1H, s, H6''), 4.76 (1H, s, H5), 3.02 (2H, t, J = 6.0 Hz, H2'), 2.95 (2H, t, J = 6.0 Hz, H5'), 1.57–1.46 (m, 2H, H4''), 1.43 (s, 9H, 3 \times CH $_3$), 1.34–1.28 (m, 2H,

H3''). ^{13}C NMR (126 MHz, CDCl_3) δ 164.1 (C4), 156.5 (O=C=O), 154.7 (C2), 151.6 (C6), 134.4 (C1'), 132.1 (C3' and C5'), 128.2 (C2' and C6'), 121.8 (C4'), 79.5 (O—C), 75.5 (C5), 43.9 (NCH₂), 43.3 (C2''), 39.6 (C5''), 28.4 (3 \times CH₃), 27.8 (C3''), 24.4 (C4'). HRMS (ES⁺) m/z calculated for C₂₀H₂₈⁷⁹BrN₄O₄. [M + H]⁺: 467.1288; found: 467.1285.

4.4. Tert-butyl (4-((5-bromo-3-(4-bromobenzyl)-2,6-dioxo-1,2,3,6-tetrahydropyrimidin-4-ylamino)butyl)carbamate (6d)

N-Bromosuccinimide (500.0 mg, 2.7 mmol, 1.1 eq.) was added portion-wise to a suspension of 1-benzyl-6-aminouracil **4d** (1.2 g, 2.6 mmol, 1.0 eq.) in anhydrous MeOH (13.0 mL, 5.0 mL/mmol) at 0 °C. The resulting yellow solution was stirred at ambient temperature for 10 mins under nitrogen. The solvent was evaporated *in vacuo* and the crude product was purified by column chromatography (20% EtOAc in petroleum ether). **6d** was obtained as a yellow solid (1.2 g, 2.2 mmol, 85%). Mp. 283–286 °C. 3227 (N—H), 2980 (C—H), 1746 (C=O), 1665 (C=C), 1674 (C=O), 1643 (N—H), 1379 (C—N), 1365 (C—H), 1302 (C—N), 1165 (C—O), 754 (Ar C—H), 636 (C—Br). ^1H NMR (500 MHz, CDCl_3) δ 8.65 (1H, s, H3), 7.55–7.47 (2H, m, H3' and H5'), 7.17–7.12 (2H, m, H2' and H6'), 5.13 (2H, s, NCH₂), 4.64 (1H, brs, H1''), 4.44 (1H, s, H6''), 3.24 (2H, t, $J = 6.7$ Hz, H5''), 3.10 (2H, t, $J = 6.7$ Hz, H2''), 1.63–1.51 (2H, m, H4''), 1.46–1.43 (11H, m, H3' and 3 \times CH₃). ^{13}C NMR (126 MHz, CDCl_3) δ 159.1 (C4), 156.1 (O=C=O), 154.6 (C2), 150.7 (C6), 134.5 (C1'), 132.2 (C3' and C5'), 128.3 (C2' and C6'), 122.1 (C4'), 81.5 (O—C), 79.6 (C5), 48.4 (NCH₂), 47.7 (C5''), 39.7 (C2''), 28.4 (3 \times CH₃), 27.8 (C4''), 27.3 (C3''). HRMS (ES⁺) m/z calculated for C₂₀H₂₇⁷⁹Br₂N₄O₄. [M + H]⁺: 545.0394; found: 545.0389.

4.5. Tert-butyl (4-((3-(4-bromobenzyl)-5-(methylamino)-2,6-dioxo-1,2,3,6-tetrahydropyrimidin-4-yl)amino)butyl)carbamate (7d)

The brominated intermediate **6d** (500.0 mg, 0.9 mmol) was suspended in a 40% aqueous solution of methylamine (0.5 mL, 0.5 mL/mmol). The suspension was heated to 70 °C and stirred for 1 h. The reaction was then cooled to rt. and the mixture was diluted and extracted with DCM three times (5.0 mL \times 3, 5.0 mL/mmol \times 3). The combined organic phases were washed with saturated aqueous NaCl (5.0 mL, 5.0 mL/mmol), dried over anhydrous Na₂SO₄ and concentrated *in vacuo*. The crude product was purified by column chromatography (50% acetone in petroleum ether with 1% Et₃N). **7d** was obtained as a yellow solid (300.0 mg, 0.6 mmol, 67%). Mp. 203–205 °C. ν_{max} cm⁻¹ 3333 (N—H), 2928 (C—H), 1678 (C=O), 1661 (C=O), 1526 (N—H), 1487 (C=C), 1400 (C—N), 1161 (C—C(=O)-O), 712 (Ar C—H), 575 (C—Br). ^1H NMR (500 MHz, CDCl_3) δ 8.69 (1H, s, H3), 7.53–7.47 (2H, m, H3' and H5'), 7.14 (2H, d, $J = 8.4$ Hz, H2' and H6'), 5.07 (2H, s, NCH₂), 4.93 (1H, t, $J = 6.2$ Hz, H1''), 4.62 (1H, s, H6''), 3.17 (2H, t, $J = 6.7$ Hz, H5''), 3.08 (2H, t, $J = 6.6$ Hz, H2''), 2.51 (3H, s, N_{5a}CH₃), 1.60–1.49 (2H, m, H4''), 1.46 (9H, s, 3 \times CH₃), 1.20–1.09 (2H, m, H3''). ^{13}C NMR (126 MHz, CDCl_3) δ 161.7 (C4), 156.0 (O=C=O), 150.6 (C2 and C6), 135.0 (C1'), 132.1 (C3' and C5'), 128.1 (C2' and C6'), 121.8 (C4'), 106.7 (C5), 79.4 (O—C), 47.4 (NCH₂), 46.2 (C5''), 39.9 (C2''), 36.5 (N_{5a}CH₃), 29.7 (C3''), 28.4 (3 \times CH₃), 27.7 (C4'). HRMS (ES⁺) m/z calculated for C₂₁H₃₁⁷⁹BrN₅O₄. [M + H]⁺: 496.1550; found: 496.1554.

4.6. N-(6-((4-aminobutyl)amino)-1-(4-bromobenzyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-N-methylbenzenesulfonamide (1d)

To a stirred solution of the amine **7d** (150.0 mg, 0.3 mmol, 1.0 eq.) in dry DCM (2.0 mL, 7.0 mL/mmol) was added pyridine (0.1 mL, 1.5 mmol, 5.0 eq.) followed by sulfonyl chloride (80.0 mg, 0.5 mmol, 1.5 eq.). The resulting yellow solution was stirred at rt for 18 h. The solvent was removed *in vacuo* and water (2.0 mL, 7.0 mL/mmol) was added to the residue followed by 1 M HCl to reach acidic pH to get the crude of **8d**. To a solution of **8d** in DCM (1.5 mL, 5.0 mL/mmol) was added trifluoroacetic acid (0.3 mL, 1.0 mL/mmol). The solution was allowed to stir at

room temperature overnight. The mixture was basified with ammonia solution (1.0 mL, 3.0 mL/mmol) and was extracted with DCM three times (5.0 mL \times 3, 15.0 mL/mmol). The combined organic phases were washed with saturated aqueous NaCl (5.0 mL, 15.0 mL/mmol), dried over anhydrous Na₂SO₄ and concentrated *in vacuo*. The crude product was purified by column chromatography (50% acetone in petroleum ether with 1% Et₃N). **1d** was obtained as a yellow solid (77.6 mg, 0.1 mmol, 48 %). Mp. 311–313 °C. ν_{max} cm⁻¹ 3382 (N—H), 2961 (C—H), 2922 (C—H), 1651 (C=O), 1570 (N—H), 1541 (N—H), 1447 (C=C), 1328 (C—N), 1259 (S=O), 796 (Ar C—H), 597 (C—Br). ^1H NMR (500 MHz, CDCl_3) δ 7.86–7.80 (2H, m, H3' and H5'), 7.60–7.53 (1H, m, H4''), 7.55–7.45 (4H, m, H2''), H3''), H5'') and H6''), 7.18–7.13 (2H, m, H2' and H6'), 5.23 (1H, d, $J = 16.9$ Hz, NCH₂), 5.04 (1H, d, $J = 16.9$ Hz, NCH₂), 3.75–3.61 (1H, m, H2''), 3.24–3.17 (1H, m, H2''), 3.18 (3H, s, NCH₃), 2.74–2.62 (2H, m, H5''), 1.69–1.59 (1H, m, H3''), 1.58–1.50 (1H, m, H3''), 1.47–1.39 (2H, m, H4''). ^{13}C NMR (126 MHz, CDCl_3) δ 160.1 (C4), 156.1 (C2), 150.5 (C6), 138.4 (C1''), 134.5 (C1'), 132.9 (C4''), 132.2 (C3' and C5'), 128.6 (C2', C6'), 128.0 (C3''), C5''), 127.9 (C2' and C6''), 121.9 (C4'), 95.4 (C5), 46.5 (NCH₂), 46.4 (C2''), 40.7 (C5''), 38.1 (NCH₃), 29.8 (C4''), 27.2 (C3''). HRMS (ES⁺) m/z calculated for C₂₂H₂₇⁷⁹BrN₅O₄S. [M + H]⁺: 536.0962; found: 550.0958.

4.7. N-(1-(4-bromobenzyl)-6-((3-(methylamino) propyl) amino)-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-N-methylbenzenesulfonamide (1b)

To a stirred solution of the amine **7b** (150.0 mg, 0.3 mmol, 1.0 eq.) in dry DCM (2.0 mL, 7.0 mL/mmol) was added pyridine (0.1 mL, 1.5 mmol, 5.0 eq.) followed by sulfonyl chloride (80.0 mg, 0.5 mmol, 1.5 eq.). The resulting yellow solution was stirred at rt for 18 h. The solvent was removed *in vacuo* and water (2.0 mL, 7.0 mL/mmol) was added to the residue followed by 1 M HCl to reach acidic pH to get the crude of **8d**. To a solution of **8d** in DCM (1.5 mL, 5.0 mL/mmol) was added trifluoroacetic acid (0.3 mL, 1.0 mL/mmol). The solution was allowed to stir at room temperature overnight. The mixture was basified with ammonia solution (1.0 mL, 3.0 mL/mmol) and was extracted with DCM three times (5.0 mL \times 3, 15.0 mL/mmol). The combined organic phases were washed with saturated aqueous NaCl (5.0 mL, 15.0 mL/mmol), dried over anhydrous Na₂SO₄ and concentrated *in vacuo*. The crude product was purified by column chromatography (50% acetone in petroleum ether with 1% Et₃N). **1b** was obtained as a yellow solid (81.0 mg, 0.2 mmol, 50 %). Mp. 294–297 °C. ν_{max} cm⁻¹ 3362 (N—H), 3292 (N—H), 3120 (C—H), 1709 (C=O), 1603 (C=O), 1550 (N—H), 1502 (C=C), 1173 (C—N), 750 (Ar C—H), 672 (C—Br). ^1H NMR (500 MHz, MeOD) δ 7.85–7.79 (m, 2H, H3' and H5'), 7.68–7.60 (m, 1H, H4''), 7.63–7.51 (m, 4H, H2''), H6''), H5'') and H3''), 7.23 (d, $J = 8.3$ Hz, 2H, H2' and H6'), 5.34–5.22 (m, 2H, NCH₂), 3.78 (dt, $J = 13.5$, 6.8 Hz, 1H, H2''), 3.48 (dt, $J = 13.4$, 6.8 Hz, 1H, H2''), 3.21 (s, 3H, N4'aCH₃), 2.65 (t, $J = 7.5$ Hz, 2H, H4''), 2.49 (s, 3H, N5aCH₃), 1.87–1.77 (m, 2H, H3''). ^{13}C NMR (126 MHz, MeOD) δ 161.6 (C4), 154.9 (C2), 150.6 (C6), 138.7 (C1''), 135.0 (C1'), 132.6 (C4''), 131.7 (C3' and C5'), 128.4 (C2', C6'), 127.8 (C3''), C5''), 127.7 (C2' and C6''), 120.8 (C4'), 94.5 (C5), 47.9 (C4''), 44.5 (NCH₂), 42.8 (C2''), 37.3 (N4'aCH₃), 33.3 (N5aCH₃), 26.5 (C3''). HRMS (ES⁺) m/z calculated for C₂₂H₂₇⁷⁹BrN₅O₄S. [M + H]⁺: 536.0962; found: 536.0958.

4.8. N-(1-(4-bromobenzyl)-6-((2-(methylamino)ethyl)amino)-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-N-methylbenzenesulfonamide (1c)

To a stirred solution of the amine **7c** (100.0 mg, 0.2 mmol, 1.0 eq.) in dry DCM (2.0 mL, 7.0 mL/mmol) was added pyridine (0.1 mL, 1.0 mmol, 5.0 eq.) followed by sulfonyl chloride (53.0 mg, 0.3 mmol, 1.5 eq.). The resulting yellow solution was stirred at rt for 18 h. The solvent was removed *in vacuo* and water (1.5 mL, 7.0 mL/mmol) was added to the residue followed by 1 M HCl to reach acidic pH to get the crude of **8c**. To

a solution of **8c** in DCM (1.0 mL, 5.0 mL/mmol) was added trifluoroacetic acid (0.2 mL, 1.0 mL/mmol). The solution was allowed to stir at room temperature overnight. The mixture was basified with ammonia solution (0.6 mL, 3.0 mL/mmol) and was extracted with DCM three times (5.0 mL \times 3). The combined organic phases were washed with saturated aqueous NaCl (3.0 mL, 15.0 mL/mmol), dried over anhydrous Na₂SO₄ and concentrated *in vacuo*. The crude product was purified by column chromatography (50% acetone in petroleum ether with 1% Et₃N). **1c** was obtained as a yellow solid (51.0 mg, 0.1 mmol, 46%) via **8c**. Mp. 283–286 °C. ν_{\max} cm⁻¹ 3501 (N–H), 2962 (C–H), 2926 (C–H), 1645 (C=O), 1573 (N–H), 1533(N–H), 1471 (C=C), 1444 (C–H), 1411 (C–N), 1257 (S=O), 1230 (C–N), 867 (Ar C–H), 684 (C–Br). ¹H NMR (500 MHz, DMSO-*d*₆) δ 10.96 (s, 1H, H3), 7.81–7.70 (m, 2H, H3'), 7.71–7.64 (m, 1H, H4'''), 7.67–7.46 (m, 4H, H2'', H3'', H5'' and H6''), 7.19 (d, *J* = 8.3 Hz, 2H, H2'), 6.50 (t, *J* = 5.6 Hz, 1H, H6a), 5.22–5.14 (m, 2H, NCH₂), 3.56 (m, 2H, H2'), 3.10 (s, 3H, N3'aCH₃), 3.05 (dt, *J* = 13.9, 7.0 Hz, 1H, H2''), 2.85 (dt, *J* = 13.5, 6.9 Hz, 1H, H2''), 2.59 (s, 3H, N5aCH₃). ¹³C NMR (126 MHz, DMSO-*d*₆) δ 160.7 (C4), 154.4 (C2), 150.5 (C6), 139.1 (C1'''), 136.8 (C1'), 133.6 (C4'''), 131.8 (C3' and C5'), 130.0 (C2', C6'), 129.2 (C3''' and C5'''), 128.8 (C2''' and C6'''), 127.4 (C4'), 94.3 (C5), 49.2 (C2''), 44.6 (NCH₂), 42.8 (C3''), 37.9 (N3'aCH₃), 35.6 (N5aCH₃). HRMS (ES⁺) *m/z* calculated for C₂₁H₂₅⁷⁹BrN₅O₄S. [M + H]⁺: 522.0611; found: 522.0622.

4.9. *N*-(6-((5-aminopentyl)amino)-1-(4-bromobenzyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-*N*-methylbenzenesulfonamide (**1e**)

To a stirred solution of the amine **7e** (150.0 mg, 0.3 mmol, 1.0 eq.) in dry DCM (2.0 mL, 7.0 mL/mmol) was added pyridine (0.1 mL, 1.5 mmol, 5.0 eq.) followed by sulfonyl chloride (80.0 mg, 0.5 mmol, 1.5 eq.). The resulting yellow solution was stirred at rt for 18 h. The solvent was removed *in vacuo* and water (2.0 mL, 7.0 mL/mmol) was added to the residue followed by 1 M HCl to reach acidic pH to get the crude of **8e**. To a solution of **8e** in DCM (1.5 mL, 5.0 mL/mmol) was added trifluoroacetic acid (0.3 mL, 1.0 mL/mmol). The solution was allowed to stir at room temperature overnight. The mixture was basified with ammonia solution (0.9 mL, 3.0 mL/mmol) and was extracted with DCM three times (5.0 mL \times 3). The combined organic phases were washed with saturated aqueous NaCl (4.5 mL, 15.0 mL/mmol), dried over anhydrous Na₂SO₄ and concentrated *in vacuo*. The crude product was purified by column chromatography (50% acetone in petroleum ether with 1% Et₃N). **1e** was obtained as a yellow solid (58.2 mg, 0.1 mmol, 36%) via **8e**. Mp. 317–319 °C. ν_{\max} cm⁻¹ 3382 (N–H), 2941 (C–H), 1657 (C=O), 1565 (N–H), 1535 (N–H), 1455 (C=C), 1320 (C–N), 1265 (S=O), 790 (Ar C–H), 603 (C–Br). ¹H NMR (500 MHz, CDCl₃) δ 7.86–7.80 (2H, m, H3' and H5'), 7.62–7.55 (1H, m, H4'''), 7.58–7.52 (2H, m, H2'' and H6''), 7.55–7.46 (2H, m, H3''' and H5'''), 7.21–7.15 (2H, m, H2' and H6'), 5.25 (1H, d, *J* = 16.6 Hz, NCH₂), 5.00 (1H, d, *J* = 16.6 Hz, NCH₂), 4.80 (1H, s, H1'''), 3.54 (1H, dt, *J* = 13.2 Hz, 7.1 Hz, H2'''), 3.43 (2H, s, H7''), 3.25–3.18 (1H, m, H2'''), 3.17 (3H, s, NCH₃), 2.67 (2H, dt, *J* = 13.7 Hz, 7.1 Hz, H6''), 1.54–1.44 (2H, m, H3''), 1.43–1.36 (2H, m, H5''), 1.28–1.23 (2H, m, H4''). ¹³C NMR (126 MHz, CDCl₃) δ 159.6 (C4), 156.5 (C2), 150.5 (C6), 138.1 (C1'''), 134.2 (C1'), 133.0 (C4'''), 132.4 (C3' and C5'), 128.7 (C2' and C6'), 128.1 (C3''' and C5'''), 128.0 (C2''' and C6'''), 122.3 (C4'), 96.5 (C5), 47.2 (NCH₂), 46.4 (C2''), 41.6 (C6''), 37.9 (NCH₃), 32.5 (C5''), 30.0 (C3''), 23.7 (C4''). HRMS (ES⁺) *m/z* calculated for C₂₃H₂₉⁷⁹BrN₅O₄S. [M + H]⁺: 550.1118; found: 550.1114.

4.10. *N*-(6-((3-azidopropyl)amino)-1-benzyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-*N*-methyl

Benzenesulfonamide (**1f**)

To a stirred solution of the amine **7f** (150.0 mg, 0.4 mmol, 1.0 eq.) in dry DCM (1.0 mL) was added pyridine (0.1 mL, 2.0 mmol, 5.0 eq.) followed by sulfonyl chloride (104.0 mg, 0.6 mmol, 1.5 eq.). The resulting

yellow solution was stirred at rt for 18 h. The solvent was removed *in vacuo*. To a solution of the crude in ⁴BuOH / H₂O (1:1, 2.0 mL) was added ascorbic acid (14.0 mg, 0.1 mmol, 0.2 eq.), CuSO₄·5H₂O (12.0 mg, 0.1 mmol, 0.2 eq.) and propargylamine (24.0 mg, 0.4 mmol, 1.1 eq.). The reaction mixture was stirred at rt. for 1 h, then quenched by addition of NH₄Cl and extracted with EtOAc (5 mL \times 3). The combined organic layers were washed with brine, dried with MgSO₄ and concentrated *in vacuo*. The crude product was purified by column chromatography (5% methanol in DCM). **1f** was obtained as a yellow solid (21.0 mg, 0.04 mmol, 10%). Mp. 295–297 °C. ν_{\max} : 3296 (N–H), 3159 (N–H), 2963 (C–H), 1699 (C=O), 1645 (C=O), 1574 (N–H), 1445 (C=C), 1259 (S=O), 1087 (C–N), 746 (Ar C–H) cm⁻¹. ¹H NMR (500 MHz, CD₃OD) δ 7.83–7.75 (3H, m, H2'', H6'' and H5'''), 7.66–7.59 (1H, m, H4'''), 7.53 (2H, t, *J* = 7.8 Hz, H3''' and H5'''), 7.40 (2H, t, *J* = 7.7 Hz, H2' and H6'), 7.33–7.27 (3H, m, H3', H4' and H5'), 5.49 (1H, d, *J* = 17.2 Hz, NCH₂), 5.16 (1H, d, *J* = 17.3 Hz, NCH₂), 4.11 (1H, dt, *J* = 13.3, 6.5 Hz, H4''), 4.03 (1H, dt, *J* = 13.8, 6.8 Hz, H4''), 3.99 (2H, s, H1'''), 3.65–3.59 (1H, m, H2''), 3.35–3.30 (1H, m, H2''), 3.09 (3H, s, NCH₃), 2.06 (1H, dt, *J* = 13.8, 6.9 Hz, H3''), 1.99 (1H, dt, *J* = 14.1, 7.0 Hz, H3''). ¹³C NMR (126 MHz, CD₃OD) ¹³C NMR (126 MHz, CD₃OD) δ 161.3 (C4), 155.0 (C2), 150.8 (C6), 145.8 (C4'''), 138.8 (C1'''), 135.6 (C1'), 132.6 (C2''' and C6'''), 128.8 (C4'''), 128.4 (C2' and C6'), 127.8 (C3''' and C5'''), 127.5 (C4'), 125.7 (C3' and C5'), 122.9 (C5'''), 94.3 (C5), 46.9 (C4''), 46.27, 44.9 (NCH₂), 42.1 (C2''), 37.1 (NCH₃), 29.60 (C3'). HRMS (ES⁺) *m/z* calculated for C₂₄H₂₉N₈O₄S. [M + H]⁺: 525.2027; found: 525.2022.

4.11. Cloning, expression and purification

P. aeruginosa RmlA was cloned, expressed and purified based on protocols previously reported.³²

4.12. *In vitro* biological assays

Each assay was performed in a 101 μ L reaction volume containing 50 mM Tris (pH 7.4), 5 mM MgCl₂, 1 mM dithiothreitol, 0.1 mM EDTA (pH 8.0), 0.1 mM EGTA (pH 8.0), 0.05% NP-40, 15 nM recombinant RmlA, 0.8 μ g/ml pyrophosphatase, 5 μ M dTTP and 5 μ M G-1-P. The inhibitor was added to the plate (20 μ L) followed by RmlA (30 μ L). The reaction was initiated with the addition of dTTP (25 μ L), G-1-P (25 μ L) and pyrophosphatase (1 μ L) as a mixture in one charge (51 μ L total) and the assay was allowed to run for 30 min at room temperature. The reaction was quenched by addition of BIOMOL™ Green reagent (100 μ L) and was allowed to develop before the absorbance of each well was measured at 620 nm.

4.13. Protein Crystallization, co-Crystallization and soaking

Crystals were grown by the sitting drop vapour diffusion method as previously described.⁷ Drops contained 1 μ L of protein (10 mg mL⁻¹ mixed with 1 μ L precipitant (4–12% PEG 6000, 0.1–0.15 M MES pH 6.0, 0.05–0.1 M MgCl₂, 0.1–0.15 M NaBr, 1% β -mercaptoethanol). Crystals grew overnight to dimensions of 0.2 \times 0.2 \times 0.1 mm. Complexes of RmlA with inhibitor were prepared by soaking or co-crystallization. For soaking, solid compound was added to drops containing crystals and allowed to incubate for between 2 and 24 h prior to data collection. For co-crystallization, solid compound was incubated with protein in solution for 1 h prior to setting up sitting drops.

4.14. Data collection

Data were collected at the Diamond Light Source synchrotron or in-house using a Rigaku MicroMax 007HFM x-ray generator. Data were processed with iMOSFLM³³ or XIA2³⁴ incorporating XDS³⁵. Each structure was solved using MOLREP³⁶ with 4ASJ⁷ as the search model with the inhibitor removed. REFMAC³⁷ was used to refine the models

with model building in COOT³⁸ and ligands built with PRODRG³⁹. Structural figures were prepared using Pymol⁴⁰ and CCP4MG⁴¹.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgements

This work was supported by grants from The Scottish Universities Life Science Alliance (L.P., Ph.D. studentship), a China Scholarship Council-University of St Andrews PhD Fellowship (GX). JHN is funded by the Wellcome Trust (100209/Z/12/Z). We would like to thank Dr Christopher Lancefield for helpful discussions.

The coordinates of the RmlA complexes have been deposited in the Protein Data Bank (pdb codes 5FUH, 5FYE, 5FUO, 5FTS, 5FTV, 5FU8, 6TQG, 6T38, 6T37).

Raw data files can be found at DOI: 10.6084/m9.figshare.16657876.

Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.bmc.2021.116477>.

References

- [1] Lewis K. Platforms for antibiotic discovery. *Nat Rev Drug Discov.* 2013;12:371–387.
- [2] Schwechheimer C, Kuehn MJ. Outer-membrane vesicles from Gram-negative bacteria: biogenesis and functions. *Nat Rev Microbiol.* 2015;13:605–619.
- [3] Blankenfeldt W, Asuncion M, Lam JS, Naismith JH. The structural basis of the catalytic mechanism and regulation of glucose-1-phosphate thymidyltransferase (RmlA). *EMBO J.* 2000;19:6652–6663.
- [4] Vilchèze C. Mycobacterial Cell Wall: A Source of Successful Targets for Old and New Drugs. *Appl Sci.* 2020;10:1–35.
- [5] McNeil M, Brennan P. Structure function and biogenesis of the cell envelope of mycobacteria in relation to bacterial physiology, pathogenesis and drug resistance; some thoughts and possibilities arising from recent structural information. *Res Microbiol.* 1991;142:451–463.
- [6] Lucas R, Balbuena P, Errey JC, Squire MA, Gurcha SS, McNeil M, Besra GS, Davis BG. Glycomimetic inhibitors of mycobacterial glycosyltransferases: targeting the TB cell wall. *ChemBioChem* 2008; 9; 2197–2199.
- [7] Alphey MS, Pirrie L, Torrie LS, et al. Allosteric competitive inhibitors of the glucose-1-phosphate thymidyltransferase (RmlA) from *Pseudomonas aeruginosa*. *ACS Chem Biol.* 2012;8:387–396.
- [8] Loranger MW, Forget SM, McCormick NE, Syvitski RT, Jakeman DL. Synthesis and evaluation of L-rhamnose 1C-phosphonates as nucleotidyltransferase inhibitors. *J Org Chem.* 2013;78:9822–9833.
- [9] Loranger MW. *The Design and Synthesis of Phosphonate-based Inhibitors of Nucleotidyltransferases*. PhD Thesis. Dalhousie University; 2013.
- [10] Sivendran S, Jones V, Sun D, et al. Identification of triazinoindol-benzimidazolones as nanomolar inhibitors of the *Mycobacterium tuberculosis* enzyme TDP-6-deoxy-D-xylo-4-hexopyranosid-4-ulose 3, 5-epimerase (RmlC). *Bioorg Med Chem.* 2010;18: 896–908.
- [11] Harathi N, Pulaganti M, Anuradha CM, Kumar CS. Inhibition of mycobacterium-RmlA by molecular modeling, dynamics simulation, and docking. *Adv Bioinform.* 2016:1–13.
- [12] Sivaraman J, Sauvè V, Matte A, Cygler M. Crystal structure of *Escherichia coli* glucose-1-phosphate thymidyltransferase (RifH) complexed with dTTP and Mg²⁺. *J Biol Chem.* 2002;277:44214–44219.
- [13] Zuccotti S, Zanardi D, Rosano C, Sturla L, Tonetti M, Bolognesi M. Kinetic and crystallographic analyses support a sequential-ordered bi catalytic mechanism for *Escherichia coli* glucose-1-phosphate thymidyltransferase. *J. Mol. Biol.* 2001; 313:831–843.
- [14] Barton WA, Lesniak J, Biggins JB, et al. Structure, mechanism and engineering of a nucleotidyltransferase as a first step toward glycorandomization. *Nat Struct Mol Biol.* 2001;8:545.
- [15] Qu H, Xin Y, Dong X, Ma Y. An rmlA gene encoding d-glucose-1-phosphate thymidyltransferase is essential for mycobacterial growth. *FEMS Microbiol Lett.* 2007;275:237–243.
- [16] Brennan PJ. Structure, function, and biogenesis of the cell wall of *Mycobacterium tuberculosis*. *Tuberculosis.* 2003;83:91–97.
- [17] Camacho LR, Constant P, Raynaud C, et al. Analysis of the phthiocerol dimycoserate locus of *Mycobacterium tuberculosis*. *J Biol Chem.* 2001;276: 19845–19854.
- [18] Panovic I, Montgomery JR, Lancefield CS, Puri D, Lebl T, Westwood NJ. Grafting of technical lignins through regioselective triazole formation on β-O-4 linkages. *ACS Sustain Chem Eng.* 2017;5:10640–10648.
- [19] Ishikawa I, Itoh T, Melik-ohanjanian R, et al. Synthesis and X-ray analysis of 1-benzyl-6-chlorouracil. *ChemInform.* 1991;22:1641–1646.
- [20] Gasparyan S, Alexanyan M, Arutyunyan G, et al. Synthesis of new derivatives of 5-(3, 4-dihydro-2 H-pyrrrol-5-yl)-pyrimidine. *Russ J Org Chem.* 2016;52:1646–1653.
- [21] In response to the question raised during the review of this manuscript, the following additional insights were gained in order to explain the possible reasons why **1c** lost the inhibitory activity: (1) Based on X-ray crystallographic analysis of **1b** (3 CH₂) bound in the allosteric site of *P. aeruginosa* RmlA (Figure S4 in ESI), there was a water network to stabilise the terminus NH group in **1b** (3 CH₂), while the same water mediated interactions might be not so tight in **1c** (2 CH₂) leaving the aminoalkyl chain in **1c** free to move around; (2) Based on the molecular docking result (Figure S5 in ESI), the pyrimidinedione core in **1c** was predicted to be shifted compared to that in **8a** (a C6-NH₂ compound in the original series). One possibility of the activity loss of **1c** might be that the key interactions between pyrimidinedione core in **1c** and *P. aeruginosa* RmlA might be weakened or lost.
- [22] Leeson PD, Springthorpe B. The influence of drug-like concepts on decision-making in medicinal chemistry. *Nat. Rev. Drug Discov.* 2007;6:881–890.
- [23] Macielag MJ. Chemical properties of antimicrobials and their uniqueness. In: *Antibiotic Discovery and Development*. Springer; 2012:793–820.
- [24] Möllmann U, Heinisch L, Bauernfeind A, Köhler T, Ankel-Fuchs D. Siderophores as drug delivery agents: application of the “Trojan Horse” strategy. *Biometals.* 2009; 22:615–624.
- [25] Mislin GL, Chalk IJ. Siderophore-dependent iron uptake systems as gates for antibiotic Trojan horse strategies against *Pseudomonas aeruginosa*. *Metalomics.* 2014;6:408–420.
- [26] Miller MJ, Malouin F. Microbial iron chelators as drug delivery agents: the rational design and synthesis of siderophore-drug conjugates. *Acc. Chem. Res.* 1993;26: 241–249.
- [27] Ghosh A, Ghosh M, Niu C, Malouin F, Moellmann U, Miller MJ. Iron transport-mediated drug delivery using mixed-ligand siderophore-β-lactam conjugates. *Chem. Biol.* 1996;3:1011–1019.
- [28] Möllmann U, Ghosh A, Dolence EK, et al. Selective growth promotion and growth inhibition of Gram-negative and Gram-positive bacteria by synthetic siderophore-β-lactam conjugates. *Biometals.* 1998;11:1–12.
- [29] Richter MF, Drown BS, Riley AP, et al. Predictive compound accumulation rules yield a broad-spectrum antibiotic. *Nature.* 2017;545:299–304.
- [30] Richter MF, Hergenrother PJ. The challenge of converting Gram-positive-only compounds into broad-spectrum antibiotics. *Ann. N. Y. Acad. Sci.* 2019;1435: 18–38.
- [31] Górka A, Sloderbach A, Marszał MP. Siderophore–drug complexes: potential medicinal applications of the ‘Trojan horse’ strategy. *Trends Pharmacol. Sci.* 2014; 35:442–449.
- [32] Giraud MF, Leonard G, Rahim R, Creuzenet C, Lam J, Naismith J. The purification, crystallization and preliminary structural characterization of glucose-1-phosphate thymidyltransferase (RmlA), the first enzyme of the dTDP-L-rhamnose synthesis pathway from *Pseudomonas aeruginosa*. *Acta Crystallogr Sect D: Biol Crystallogr.* 2000;56:1501–1504.
- [33] Leslie A. The integration of macromolecular diffraction data. *Acta Crystallogr Sect D: Biol Crystallogr.* 2006;62:48–57.
- [34] Winter G. xia2: an expert system for macromolecular crystallography data reduction. *J. Appl. Crystallogr.* 2010;43:186–190.
- [35] Kabsch W. XDS. *Acta Crystallogr Sect D: Biol Crystallogr.* 2010;66:125–132.
- [36] Vagin A, Teplyakov A. Molecular replacement with MOLREP. *Acta Crystallogr Sect D: Biol Crystallogr.* 2010;66:22–25.
- [37] Murshudov GN, Vagin AA, Dodson EJ. Refinement of Macromolecular Structures by the Maximum-Likelihood Method. *Acta Crystallogr Sect D: Biol Crystallogr.* 1997; 53:240–255.
- [38] Emsley P, Cowtan K. Coot: model-building tools for molecular graphics. *Acta Crystallogr Sect D: Biol Crystallogr.* 2004;60:2126–2132.
- [39] Schüttelkopf AW, Van Aalten DMF. PRODRG: a tool for high-throughput crystallography of protein-ligand complexes. *Acta Crystallogr Sect D: Biol Crystallogr.* 2004;60:1355–1363.
- [40] Schrödinger L, DeLano W. Pymol. The PyMOL Molecular Graphics System; Version; 2020:2.
- [41] McNicholas S, Potterton E, Wilson KS, Noble MEM. Presenting your structures: the CCP4mg molecular-graphics software. *Acta Crystallogr Sect D: Biol Crystallogr.* 2011;67:386–394.